Medicare Part D coverage · lithium carbonate · RxCUI 206786

lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]

Per the CMS 2026 Part D formulary file, lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] is covered by 2 Medicare Part D plans (0% of enrollable products), averaging Tier 1, with prior authorization required on 0% of covering formularies.

0%
Plan coverage
2
Plans covering
T1
Avg tier
0%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]

Per the CMS 2026 Part D formulary file, lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] (RxNorm concept RXCUI 206786, generic name lithium carbonate) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.

Real-world access to lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 103,265 Part D beneficiaries filled lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] in 2023, with total plan-and-beneficiary spending of $7,437,848 and an average per-beneficiary annual cost of $72.03. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] today.

Coverage Details

Formularies covering
1
Plans covering
2
Coverage rate
0%
Tier range
Tier 1, Preferred Generic
Average tier
Tier 1, Preferred Generic

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
103,265
Total spending
$7,437,848
Avg per beneficiary
$72.03

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic

Medicare Advantage Plans (MA-PD) Covering lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]

2 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) Hamaspik, Inc. T1 No $0 NY
Hamaspik Medicare Select (HMO D-SNP) Hamaspik, Inc. T1 No $34.50 NY

Frequently Asked Questions

Is lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] covered by Medicare Part D?

Yes, lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] is covered by 2 Medicare Part D plans (0% of all Part D formularies).

What tier is lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] on Medicare Part D plans?

lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.

Does lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] require prior authorization?

0% of Part D formularies require prior authorization for lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid]?

In 2023, total Medicare Part D spending on lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] was $7,437,848, covering 103,265 beneficiaries. The average spend per beneficiary was $72.03.

Read our methodology - how this data is sourced, computed, and verified.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Closest average formulary tier

Similar prior-authorization rate

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare